The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung Cancer
Open accessAbstract
Epigenetic alterations are strongly associated with the development of cancer. We conducted a phase I/II trial of combined epigenetic therapy with azacitidine and entinostat, inhibitors of DNA methylation and histone deacetylation, respectively, in extensively pretreated patients with recurrent metastatic non–small cell lung cancer. This therapy is well tolerated, and objective responses were observed, including a complete response and a partial response in a patient who remains alive and without disease progression approximately 2 years after completing protocol therapy. Median survival in the entire cohort was 6.4 months (95% CI 3.8–9.2), comparing favorably with existing therapeutic options. Demethylation of a set of 4 epigenetically silenced genes known to be associated with lung cancer was detectable in serial blood samples in these patients and was associated with improved progression-free (P = 0.034) and overall survival (P = 0.035). Four of 19 patients had major objective responses to subsequent anticancer therapies given immediately after epigenetic therapy. Significance: This study demonstrates that combined epigenetic therapy with low-dose azacitidine and entinostat results in objective, durable responses in patients with solid tumors and defines a blood-based biomarker that correlates with clinical benefit. Cancer Discovery; 1(7); 598–607. ©2011 AACR. Read the Commentary on this article by Rodríguez-Paredes and Esteller, p. 557 This article is highlighted in the In This Issue feature, p. 539
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
Self-citationJones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Self-citationGene Silencing in Cancer in Association with Promoter Hypermethylation
Herman, J. G., & Baylin, S. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023075 · Cited by 3,422
Self-citationAnticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“Other classes of HDACs shuttle between the nucleus and cytoplasm, or are predominantly cytoplasmic, and target a much broader array of protein targets (17, 18).”
BackgroundA Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
TROTTI, A., COLEVAS, A., SETSER, A., RUSCH, V, JAQUES, D., BUDACH, V, LANGER, C., MURPHY, B., CUMBERLIN, R., & COLEMAN, C. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00031-6 · Cited by 2,569
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Self-citationCameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Self-citationSilverman, L. R., Demakos, E. P., Peterson, B. L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D., Powell, B. L., DeCastro, C. M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.117 · Cited by 1,825
Cancer epigenetics reaches mainstream oncology
Rodríguez-Paredes, M., & Esteller, M. (2011) · Nature Medicine · doi:10.1038/nm.2305 · Cited by 1,205
Esteller, M., Sánchez‐Céspedes, M., Rosell, R., Sidransky, D., Baylin, S. B., & Herman, J. G. (1999) · PubMed · Cited by 921
Self-citationGandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6208 · Cited by 603
Self-citationDNA Methylation Markers and Early Recurrence in Stage I Lung Cancer
Brock, M. V., Hooker, C. M., Ota-Machida, E., Han, Y., Guo, M., Ames, S., Glöckner, S., Piantadosi, S., Gabrielson, E., Pridham, G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706550 · Cited by 593
Self-citationQuantification of Free Circulating DNA As a Diagnostic Marker in Lung Cancer
Sozzi, G., Conte, D., Leon, M., Cirincione, R., Roz, L., Ratcliffe, C., Roz, E., Cirenei, N., Bellomi, M., Pelosi, G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.006 · Cited by 552
Inhibition of DNA Methylation and Reactivation of Silenced Genes by Zebularine
Cheng, J. C., Matsen, C. B., Gonzales, F. A., Ye, W., Greer, S., Marquez, V. E., Jones, P. A., & Selker, E. U. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.399 · Cited by 535
Gore, S. D., Baylin, S., Sugar, E., Carraway, H., Miller, C. B., Carducci, M., Grever, M., Galm, O., Dauses, T., Karp, J. E., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0080 · Cited by 474
Self-citationHistone deacetylase inhibitors in cancer therapy
Johnstone, R. W., & Licht, J. D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00165-x · Cited by 449
Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases
Hu, E., Dul, E., Sung, C.-M., Chen, Z., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Liu, R., Lago, A., Hofmann, G., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055541 · Cited by 347
Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer.
Belinsky, S. A., Klinge, D. M., Stidley, C. A., Issa, J. J., Herman, J. G., March, T. H., & Baylin, S. B. (2003) · PubMed · Cited by 293
Self-citationFandy, T. E., Herman, J. G., Kerns, P., Jiemjit, A., Sugar, E. A., Choi, S.-H., Yang, A. S., Aucott, T., Dauses, T., Odchimar-Reissig, R., et al. (2009) · Blood · doi:10.1182/blood-2009-02-203547 · Cited by 282
Self-citationShepherd, F. A., Pereira, J. R., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Bezjak, A., Tu, D., Santabarbara, P., & Seymour, L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.7022 · Cited by 281
Garcia-Manero, G., Gore, S. D., Cogle, C., Ward, R., Shi, T., MacBeth, K. J., Laille, E., Giordano, H., Sakoian, S., Jabbour, E., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4226 · Cited by 252
Momparler, R. L., Bouffard, D. Y., Momparler, L. F., Dionne, J., B??langer, K., & Ayoub, J. (1997) · Anti-Cancer Drugs · doi:10.1097/00001813-199704000-00008 · Cited by 210
Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
Shoemaker, A. R., Mitten, M. J., Adickes, J., Ackler, S., Refici, M., Ferguson, D., Oleksijew, A., O'Connor, J. M., Wang, B., Frost, D. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4622 · Cited by 203
Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions
Marks, P. A. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.05.008 · Cited by 187
Vansteenkiste, J., Van Cutsem, E., Dumez, H., Chen, C., Ricker, J. L., Randolph, S. S., & Schöffski, P. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9131-6 · Cited by 174
Braiteh, F., Soriano, A. O., Garcia-Manero, G., Hong, D., Johnson, M. M., Silva, L. D. P., Yang, H., Alexander, S., Wolff, J., & Kurzrock, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1247 · Cited by 164
Geng, L., Cuneo, K. C., Fu, A., Tu, T., Atadja, P. W., & Hallahan, D. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0049 · Cited by 163
DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update
Anglim, P. P., Alonzo, T. A., & Laird-Offringa, I. A. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-81 · Cited by 159
Kantarjian, H. M., Giles, F. J., Greenberg, P. L., Paquette, R. L., Wang, E. S., Gabrilove, J. L., Garcia‐Manero, G., Hu, K., Franklin, J. L., & Berger, D. P. (2010) · Blood · doi:10.1182/blood-2010-03-274753 · Cited by 152
Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0135 · Cited by 126
Self-citationRudek, M. A., Zhao, M., He, P., Hartke, C., Gilbert, J., Gore, S. D., Carducci, M. A., & Baker, S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.450 · Cited by 109
Self-citationClinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2007) · Clinical Lung Cancer · doi:10.1016/s1525-7304(11)70818-x · Cited by 97
Self-citationCirculating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer
Sirera, R., Bremnes, R. M., Cabrera‐Pastor, A., Lewintre, E. J., Sanmartín, E., Blasco, A., del Pozo, N., Rosell, R., Guijarro, R., Galbis, J. M., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820189a5 · Cited by 95
Brueckner, B., Rius, M., Markelova, M. R., Fichtner, I., Hals, P., Sandvold, M. L., & Lyko, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1202 · Cited by 92
Momparler, R. L., & Ayoub, J. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00397-x · Cited by 89
Lin, J., Gilbert, J., Rudek, M. A., Zwiebel, J. A., Gore, S. D., Jiemjit, A., Zhao, M., Baker, S. D., Ambinder, R. F., Herman, J. G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0567 · Cited by 83
Self-citationHerranz, M., Martín‐Caballero, J., Fraga, M. F., Ruı́z-Cabello, J., Flores, J. M., Desco, M., Márquez, V. E., & Esteller, M. (2005) · Blood · doi:10.1182/blood-2005-05-2033 · Cited by 72
Lee, Y. J., Yoon, K., Han, J., Kim, H. T., Yun, T., Lee, G. K., Kim, H. Y., & Lee, J. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0400 · Cited by 70
Ab, G., Leyland-Jones, B., Hg, C., Davies, B., & Df, H. (1987) · PubMed · Cited by 56
Rudin, C. M., Mauer, A. M., Šmakal, M., Juergens, R. A., Špelda, S., Wertheim, M. S., Coates, A., McKeegan, E. M., Ansell, P. J., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5944 · Cited by 51
Self-citationDNMT3B gene amplification predicts resistance to DNA demethylating drugs
Simó‐Riudalbas, L., Melo, S. A., & Esteller, M. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20877 · Cited by 45
Phase I study of 5-azacytidine (NSC-102816) .
Weiss, A. J., Stambaugh, J. E., Mastrangelo, M. J., et al. (1972) · PubMed · Cited by 43
Zhao, M., Rudek, M. A., He, P., Hartke, C., Gore, S. D., Carducci, M. A., & Baker, S. D. (2004) · Journal of Chromatography B · doi:10.1016/j.jchromb.2004.09.012 · Cited by 43
Self-citationJain, H. V., & Meyer‐Hermann, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-3174 · Cited by 41
A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma
Zhao, M., Rudek, M. A., Mnasakanyan, A., Hartke, C., Пили, Р., & Baker, S. D. (2006) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2006.08.006 · Cited by 16
Self-citationTreatment Strategies to Optimize Clinical Benefit in the Patient with Myelodysplastic Syndromes
List, A. F. (2008) · Cancer Control · doi:10.1177/107327480801504s04 · Cited by 15
Cited by
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
“IRF7 is frequently promoter DNA hypermethylated in cancer and the associated low basal expression can be reversed by Aza in squamous NSCLC (Wrangle et al., 2013).”
InfluentialSelf-citationRoulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang, G., Jones, P. A., Pugh, T. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.056 · Cited by 1,527
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
Metadata
- Authors
- Juergens, R. A., Wrangle, J., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N., Lee, B., Tsai, S., Delgado, I. E., Rudek, M. A., Belinsky, S. A., Herman, J. G., Baylin, S. B., Brock, M. V., & Rudin, C. M.
- Venue
- Cancer Discovery
- Published
- 2011-12-01
- Volume
- 1
- Issue
- 7
- Pages
- 598-607
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2141476381
- Cited by
- 686
- References
- 52
- FWCI
- 17.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.